"Buy Brazilian" gives 25% price premium for home grown innovation
This article was originally published in Scrip
New rules on bidding for government contracts in Brazil mean that manufacturers can charge up to 25% extra if any innovation relating to the product has taken place in the country. The law is potentially good for the pharmaceutical industry in Brazil, but Interfarma, the R&D-based pharmaceutical industry association there, warns that without a clear definition of innovation, the new law could lead to confusion and expensive legal wrangling for companies.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.